> Clinical disclaimer: This signature page synthesizes peer-reviewed evidence for practitioner education. It does not constitute medical advice. All interventions require individualized clinical assessment. Discuss changes with a qualified healthcare provider. Many findings described here are from discovery-phase studies with limited sample sizes; diagnostic and prognostic claims require prospective validation before clinical application.
Overview
Pancreatic cancer is the fifth leading cause of cancer death in Western nations. Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% of cases, with five-year survival of approximately 12%. The microbiome signature framework reveals pancreatic cancer as a convergence disease where metallomic disruption, oral-gut-tumor microbiome translocation, and mycobiome dysbiosis create an ecology that promotes carcinogenesis, evades detection, and drives therapeutic resistance.
The signature spans multiple biological kingdoms — bacteria, fungi, viruses, and phages — and multiple body compartments — oral cavity, gut, bile duct, and tumor tissue itself. The intratumoral microbiome directly mediates chemotherapy resistance through bacterial cytidine deaminase (CDD) metabolism of gemcitabine. This is not merely a biomarker story; the microbiome is a functional participant in disease progression.
This signature is built from 22 peer-reviewed papers spanning urine metallomics, tumor microbiome sequencing, a JAMA Oncology oral microbiome prospective study, Mendelian randomization, mycobiome profiling, metabolomics, and intervention trials.
Metallomic Signature
The landmark urine metallomics study by Schilling et al. (2020) demonstrated that a combined panel of Ca, Mg, Zn, and Cu achieves AUC 0.99 (sensitivity 95.2%, specificity 97.8%) for PDAC detection schilling 2020 urine metallomics pancreatic cancer.
NOTE: This is a discovery study (n=67). The AUC 0.99 result requires prospective validation in larger, independent cohorts before any diagnostic claims can be made. Discovery-phase biomarker studies routinely show performance degradation upon external validation.
| Metal | Direction | Key Evidence |
|---|---|---|
| copper | Elevated (urine, serum) | ATP7A overexpression in PDAC; Cu elevated across cancer types as near-universal biomarker zhang 2022 metallomics cancer review |
| zinc | Elevated (urine), depleted (tissue) | Disrupted ZnT/ZIP transporters (ZIP3, SLC30A); Zn isotope fractionation as novel biomarker dimension (median delta-66/64-Zn = -0.15 per mille vs +0.02 controls, p=0.002) schilling 2020 urine metallomics pancreatic cancer |
| Ca | Decreased (urine) | S100 protein dysregulation; AUC 0.796 individually schilling 2020 urine metallomics pancreatic cancer |
| Mg | Decreased (urine) | Disrupted cell proliferation; AUC 0.783 individually schilling 2020 urine metallomics pancreatic cancer |
| cadmium | Elevated | Cd increase confirmed in pancreatic cancer tissue zhang 2022 metallomics cancer review |
| Arsenic | Exposure risk | As exposure linked to pancreatic carcinogenesis; microbiome required for As detoxification |
| Se | Depleted | Impaired selenoprotein antioxidant defense zhang 2022 metallomics cancer review |
Key finding: The healthy Zn-to-Cu concentration correlation (r2=0.66) is completely abolished in PDAC (r2=0.0002), indicating fundamental disruption of metal homeostasis schilling 2020 urine metallomics pancreatic cancer.
Oral Microbiome Connection
The JAMA Oncology study by Meng et al. (2025) — a nested case-control within 122,000 individuals (445 PC cases, median 8.8-year follow-up) — established the oral microbiome as a prospective predictor of pancreatic cancer meng 2025 oral bacterial fungal microbiome pancreatic cancer risk.
| Finding | Detail |
|---|---|
| Microbial Risk Score (MRS) | 27 bacterial and fungal species combined |
| Risk magnitude | 3.44-fold increased PC risk per 1-SD increase (95% CI 2.63-4.51) |
| Key pathogens | P. gingivalis, E. nodatum, P. micra (red/orange complex periodontal pathogens) |
| Fungal component | Candida tropicalis included in MRS |
| Translocation mechanism | Hematogenous or biliary translocation of oral pathobionts and their inflammatory mediators |
| Follow-up | Median 8.8 years — oral signature predates diagnosis by nearly a decade |
This is the strongest epidemiological evidence to date linking the oral microbiome to pancreatic cancer risk, with a prospective design that addresses reverse causation.
Tumor Microbiome
PDAC tumors harbor intratumoral bacteria, confirmed by 16S rRNA FISH and LPS immunohistochemistry guo 2021 tumor microbiome basal like pdac:
| Feature | Detail |
|---|---|
| Dominant class | Gammaproteobacteria (Pseudomonas predominant) |
| Subtype variation | Basal-like PDAC enriched in Acinetobacter, Pseudomonas, Sphingopyxis — predicting significantly worse survival |
| Chemoresistance mechanism | Bacterial CDD (cytidine deaminase) metabolizes gemcitabine into its inactive form (dFdU), directly mediating chemotherapy resistance |
| Therapeutic implication | Antibiotic co-administration may restore gemcitabine sensitivity |
The tumor microbiome is not a passenger — it is a functional participant in treatment failure. Bacterial CDD activity represents a direct, targetable mechanism linking intratumoral microbiota to clinical outcomes.
Gut Microbiome
Enriched Taxa
| Taxon | Evidence | Pathogenic Mechanism |
|---|---|---|
| fusobacterium | Enriched in PDAC gut and tumor | Pro-inflammatory; oral-gut translocation; promotes NF-kB activation li 2020 gut microbiota roles pancreatic cancer |
| porphyromonas | Key MRS component (Meng 2025) | Periodontal pathogen; hematogenous translocation to pancreas meng 2025 oral bacterial fungal microbiome pancreatic cancer risk |
| streptococcus | MR risk-increasing (OR 1.712) | Causal association via MR jiang 2023 mendelian randomization gut microbiota pancreatic cancer |
| Odoribacter | MR risk-increasing (OR 1.899) | Strongest MR risk signal jiang 2023 mendelian randomization gut microbiota pancreatic cancer |
| Ruminiclostridium9 | MR risk-increasing (OR 1.976) | Causal association jiang 2023 mendelian randomization gut microbiota pancreatic cancer |
| Gammaproteobacteria | Intratumoral dominant | Pseudomonas predominant; CDD-mediated gemcitabine resistance guo 2021 tumor microbiome basal like pdac |
Depleted Taxa
| Taxon | Normal Function | Evidence |
|---|---|---|
| faecalibacterium prausnitzii | Primary butyrate producer; anti-inflammatory | Depleted; responder-enriched phages target Faecalibacterium liu 2026 gut virome anti pd1 nsclc |
| roseburia | Butyrate/propionate production | Depleted; phages targeting Roseburia enriched in immunotherapy responders liu 2026 gut virome anti pd1 nsclc |
| Romboutsia | Gut homeostasis | MR-confirmed protective (OR 0.87) across multiple sensitivity analyses daniel 2024 mendelian randomization gut bacteria metabolites pdac |
| Senegalimassilia | Gut homeostasis | MR-confirmed protective (OR 0.635) jiang 2023 mendelian randomization gut microbiota pancreatic cancer |
| SCFA producers (general) | Barrier integrity; Treg induction; anti-inflammatory | Global SCFA producer depletion drives chronic low-grade inflammation li 2020 gut microbiota roles pancreatic cancer |
Mycobiome
Oral and gut fungal communities are markedly altered in PDAC, representing a critical and often overlooked dimension of the signature:
| Finding | Detail | Source | |
|---|---|---|---|
| aspergillus as salivary biomarker | AUC 0.983 for PDAC detection | wei 2022 oral mycobiota pancreatic adenocarcinoma | |
| Cladosporium | AUC 0.969 for PDAC detection | wei 2022 oral mycobiota pancreatic adenocarcinoma | |
| Oral fungal diversity explosion | 5,022 vs 830 OTUs in PDAC vs controls (with decreased Shannon diversity) | wei 2022 oral mycobiota pancreatic adenocarcinoma | |
| **[[candida-albicans | Candida]] in pancreatitis** | Dominates fecal mycobiome at 61% in acute pancreatitis (PC precursor) | zhao 2025 intestinal fungal microbiota acute pancreatitis |
| Aspergillus-WBC correlation | Suggests fungal-driven inflammatory amplification | zhao 2025 intestinal fungal microbiota acute pancreatitis |
The mycobiome connects to the metallomic signature through fungal iron dependence: metal-driven shifts in the bacterial microbiome create ecological niches that fungi exploit, while fungal iron acquisition (siderophores) further disrupts metal ecology.
Virome
The gut virome adds a third biological kingdom to the signature:
| Finding | Detail | Source |
|---|---|---|
| Virome predicts immunotherapy response | AUC 0.768 (outperforms bacterium-only AUC 0.664) | liu 2026 gut virome anti pd1 nsclc |
| Responder-enriched phages | Target Faecalibacterium and Roseburia (SCFA producers) | liu 2026 gut virome anti pd1 nsclc |
| Non-responder phages | Target Clostridium and Bacteroides | liu 2026 gut virome anti pd1 nsclc |
| Phage-based therapeutics | Phage-derived peptides show selective PDAC targeting | li 2023 phage based peptides pancreatic cancer |
Metabolomics
| Metabolite Class | Direction | Key Evidence |
|---|---|---|
| SCFAs (butyrate, propionate) | Depleted | SCFA producer depletion → chronic inflammation → carcinogenic environment li 2020 gut microbiota roles pancreatic cancer |
| BCAAs (Leu, Ile, Val) | Elevated in tumor | Sustain PDAC growth via BCAT2/BCKDHA-driven lipogenesis lee 2019 bcaa pancreatic cancer lipid metabolism |
| Deoxycholic acid | Elevated | Promotes DNA damage via EGFR ligand amphiregulin li 2020 gut microbiota roles pancreatic cancer |
| Mannitol | Protective (MR) | OR 0.97 per unit increase — causal protective metabolite daniel 2024 mendelian randomization gut bacteria metabolites pdac |
| Methionine | Protective (MR) | OR 0.97 — causal protective metabolite daniel 2024 mendelian randomization gut bacteria metabolites pdac |
| Carnitine | Risk-increasing (MR) | Causal risk metabolite daniel 2024 mendelian randomization gut bacteria metabolites pdac |
| Serum 4-metabolite panel | Diagnostic | AUC 0.93 (xylitol, 1,5-AG, histidine, inositol) — outperforms CA19-9 in early-stage kobayashi 2013 serum metabolomics pancreatic cancer |
Ecological Features
1. Tumor microbiome subtypes: Basal-like PDAC harbors a distinct intratumoral microbiome (Acinetobacter, Pseudomonas, Sphingopyxis) that predicts worse survival. The tumor microbiome is not random colonization — it reflects selection by the tumor microenvironment guo 2021 tumor microbiome basal like pdac.
2. Gemcitabine resistance via bacterial CDD: Intratumoral Gammaproteobacteria express cytidine deaminase that converts gemcitabine to its inactive metabolite (dFdU). This is a direct, mechanistic link between the microbiome and treatment failure — not a correlation guo 2021 tumor microbiome basal like pdac.
3. Oral-pancreatic translocation: Periodontal pathogens (P. gingivalis, Fusobacterium) translocate to the pancreas via hematogenous or biliary routes. The oral MRS predates diagnosis by a median of 8.8 years, suggesting this translocation is an early event in carcinogenesis meng 2025 oral bacterial fungal microbiome pancreatic cancer risk.
4. Chronic low-grade inflammation: LPS from Gram-negative bacteria activates NF-kB and MAPK signaling. SCFA depletion removes anti-inflammatory brake. Obesity and T2D — both PC risk factors — converge on this inflammatory dysbiosis li 2020 gut microbiota roles pancreatic cancer.
5. Bile acid dysmetabolism: Altered bacterial bile acid deconjugation produces excess deoxycholic acid, which promotes DNA damage. This connects the gut microbiome to pancreatic carcinogenesis through the biliary-pancreatic anatomical axis.
Validated Interventions
Probiotic / Microbial
| Intervention | Mechanism | Evidence |
|---|---|---|
| *Ferrichrome (from L. casei)* | Siderophore-mediated iron chelation; induces p53-mediated apoptosis in PDAC cells including 5-FU-resistant lines; 10 mg/kg reduces xenograft tumor volume | Promising — preclinical; connects iron biology to ferroptosis kita 2020 ferrichrome probiotics pancreatic cancer |
| Synbiotics (probiotics + inulin) | RCT (90 patients, NCT06199752): CD8+ T cells elevated to 61.5% vs 15.8% placebo; reduced postoperative bacteremia | Validated — Phase II RCT maher 2024 synbiotics immunomodulation pdac resection |
| FMT (from long-term survivors) | Transfers protective microbiome ecology from long-term PDAC survivors; enhances anti-tumor immunity | Promising — preclinical models yamamura 2025 fmt therapeutic strategy pancreatic cancer |
| Gallium-polyphenol nanoparticles (LGG-loaded) | Reprograms intratumoral microbiota and tumor immune microenvironment | Experimental — preclinical han 2024 lgg gallium polyphenol intratumor microbiota pancreatic cancer |
Dietary
| Intervention | Mechanism | Evidence |
|---|---|---|
| Dietary fiber | Protective against PC risk; supports SCFA-producing taxa | Validated — meta-analysis confirms dose-response protective association wang 2015 dietary fiber pancreatic cancer risk meta analysis |
| Quercetin | Inhibits pancreatic cancer stem cell self-renewal; attenuates sonic hedgehog and beta-catenin signaling | Promising — preclinical zhou 2010 quercetin pancreatic cancer stem cells |
| Oral hygiene / periodontal care | Reduces oral pathobiont burden (P. gingivalis, Fusobacterium) that translocation to pancreas | Epidemiologically supported — periodontal disease is established PC risk factor; Meng 2025 MRS provides mechanism meng 2025 oral bacterial fungal microbiome pancreatic cancer risk |
STOPs
| STOP | Why It Matters |
|---|---|
| Do not overclaim diagnostic utility from discovery-phase biomarkers | The Zn isotope fractionation AUC 0.99 (Schilling 2020, n=67) and Aspergillus salivary AUC 0.983 (Wei 2022) are discovery-phase results. Discovery AUCs routinely degrade 10-20% upon external validation. These are hypothesis-generating, not clinically actionable diagnostic thresholds. Prospective validation in independent, adequately powered cohorts is required before any clinical deployment. Practitioners should NOT present these as validated diagnostic tests to patients. |
| Caution with antibiotic co-administration for gemcitabine sensitization | While bacterial CDD mediates gemcitabine resistance, broad-spectrum antibiotics would simultaneously destroy protective SCFA producers and potentially worsen overall prognosis. Targeted intratumoral antibiotic strategies require development before clinical application. |
Open Questions
- Oral microbiome screening: Can the Meng 2025 MRS (27 species) be reduced to a clinically feasible screening panel? What is the cost-effectiveness in average-risk populations?
- Intratumoral antibiotic targeting: Can narrow-spectrum antibiotics or phage therapy selectively eliminate CDD-producing Gammaproteobacteria without collateral damage?
- Mycobiome as early biomarker: Aspergillus AUC 0.983 in saliva — does this replicate in prospective validation? What is the lead time before diagnosis?
- FMT from long-term survivors: What specific taxa or metabolites from survivor microbiomes drive anti-tumor immunity? Can these be isolated?
- Virome-guided immunotherapy: Can phage profiling guide immunotherapy selection for PDAC patients?
- Metal homeostasis restoration: Does correcting the Zn/Cu ratio imbalance (r2 collapse from 0.66 to 0.0002) alter disease trajectory?
Knowledge Primitives Applied
- Metals as Selective Pressures — Cu elevation + Zn tissue depletion + Cd/As exposure creates pro-carcinogenic metal ecology
- Nutritional Immunity as Interpretive Constraint — Zn urinary elevation with tissue depletion reflects disrupted metal trafficking, not simple excess
- Mis-metallation and Toxic Metal Entry — Cd/As as carcinogenic metals; Zn isotope fractionation reflects metalloprotein dysfunction
- Microbial Metal Dependencies as Achilles' Heels — Ferrichrome (L. casei siderophore) exploits iron dependency to induce tumor cell death
- Two-Sided Ecological Engineering — Must suppress Gammaproteobacteria/Fusobacterium AND restore SCFA producers; synbiotics RCT demonstrates this approach
- Interkingdom Relationships and Functional Shielding — Bacterial-fungal cooperation (Aspergillus, Candida) in tumor ecology; trans-kingdom MRS in oral cavity
- Estrobolome and Hormone Recirculation — Not primary driver; bile acid dysmetabolism is the relevant hormone-like metabolite axis
- Siderophore Competition and Iron Ecology — Ferrichrome from L. casei induces ferroptosis in PDAC cells; fungal iron acquisition reshapes mycobiome
- Oxygen State as Ecological Determinant — Tumor hypoxia selects for anaerobic/microaerophilic intratumoral microbiome composition
Key Sources
- schilling 2020 urine metallomics pancreatic cancer
- zhang 2022 metallomics cancer review
- meng 2025 oral bacterial fungal microbiome pancreatic cancer risk
- guo 2021 tumor microbiome basal like pdac
- luo 2025 microbiome metabolome interplay pancreatic cancer
- kita 2020 ferrichrome probiotics pancreatic cancer
- daniel 2024 mendelian randomization gut bacteria metabolites pdac
- jiang 2023 mendelian randomization gut microbiota pancreatic cancer
- wei 2022 oral mycobiota pancreatic adenocarcinoma
- zhao 2025 intestinal fungal microbiota acute pancreatitis
- maher 2024 synbiotics immunomodulation pdac resection
- liu 2026 gut virome anti pd1 nsclc
- li 2020 gut microbiota roles pancreatic cancer
- kobayashi 2013 serum metabolomics pancreatic cancer
- lee 2019 bcaa pancreatic cancer lipid metabolism
- li 2023 phage based peptides pancreatic cancer
- wang 2015 dietary fiber pancreatic cancer risk meta analysis
- zhou 2010 quercetin pancreatic cancer stem cells
- yamamura 2025 fmt therapeutic strategy pancreatic cancer
- han 2024 lgg gallium polyphenol intratumor microbiota pancreatic cancer
- berrington 2003 obesity pancreatic cancer meta analysis
- huxley 2005 diabetes pancreatic cancer meta analysis